Skip to content

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

A Phase IV Study to Evaluate the Effectiveness of Flumist (Influenza Vaccine, Live Intranasal) Vaccination in a School-Based Intervention Program

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00192218
Enrollment
3022
Registered
2005-09-19
Start date
2004-10-31
Completion date
2005-04-30
Last updated
2008-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Brief summary

To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.

Interventions

BIOLOGICALFluMist

0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type

Sponsors

MedImmune LLC
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 17 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy children enrolled in the target schools. * Written informed consent obtained from the child's parent(s) if they agree to participate.

Exclusion criteria

* History of severe hypersensitivity (anaphylactic response) to egg products or previous FluMist * FluMist is licensed exclusively for use in healthy individuals age 5-49 years. Therefore children for whom annual receipt of inactivated influenza vaccine for specific medical condition(s) is recommended will not be eligible. These conditions include: * Asthma, other chronic pulmonary diseases, kidney disease, metabolic disease, heart disease, or hemoglobinopathy * Immunosuppression of child * Severe immunosuppression of a household member * Pregnancy * Past history of Guillian-Barre Syndrome * Aspirin therapy within 1 month prior to FluMist or the anticipated use of aspirin containing products for one month after FluMist administration * Administration of any inactivated vaccine within 2 weeks or any live vaccine within 4 weeks prior to receipt of FluMist * Received anti-influenza medication in the past 48 hours * Fever in the past 72 hours * Moderate to severe nasal congestion (inability to breathe through the nose) or acute phase URI symptoms until the congestion has improved

Design outcomes

Primary

MeasureTime frame
To compare the families of children in the target schools with families of children in the control schools with respect to workdays lost by adults and school days lost by children.7 days after each vaccination

Secondary

MeasureTime frame
Absenteeism - To compare the families of children in the target schools to those in the control schools with respect to the overall increase in absenteeism during the influenza outbreak, using aggregated (summary) absentee rates.between outbreak and non-outbreak weeks
Herd Community - To compare unvaccinated children in the target schools to the children in the control schools with respect to changes in absentee rates between outbreak weeks and non-outbreak weeks.between outbreak and non-outbreak weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 8, 2026